Person:
KARALI, YASİN

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

KARALI

First Name

YASİN

Name

Filters

Reset filters

Settings

Search Results

Now showing 1 - 10 of 21
  • No Thumbnail Available
    Publication
    T-cell/histiocyte-rich large B-cell lymphoma in a patient with a novel frameshift MSH6 mutation
    (Wiley, 2022-09-24) Çekiç, Şükrü; Aydın, Firdevs; Karalı, Yasin; Sevinir, Betül Berrin; Canöz, Özlem; Boztuğ, Kaan; Ünal, Ekrem; Kılıç, Sara Şebnem; ÇEKİÇ, ŞÜKRÜ; KARALI, YASİN; SEVİNİR, BETÜL BERRİN; KILIÇ GÜLTEKİN, SARA ŞEBNEM; Tıp Fakültesi; Pediatrik İmmünoloji Ana Bilim Dalı; 0000-0002-9574-1842; 0000-0002-3232-7652; 0000-0002-2691-4826; 0000-0001-8571-2581; ISC-9139-2023; L-1933-2017; AAH-1658-2021; AAH-1570-2021
  • No Thumbnail Available
    Publication
    Omalizumab treatment in childhood chronic urticaria
    (Wiley, 2018-08-01) Çekiç, Şükrü; Karali, Yasin; Canıtez, Yakup; Sapan, Nihat; ÇEKİÇ, ŞÜKRÜ; KARALI, YASİN; CANITEZ, YAKUP; SAPAN, NİHAT; Tıp Fakültesi; Pediatri ve Alerji Bölümü; 0000-0002-9574-1842; L-1933-2017; FFS-1974-2022; CJQ-2060-2022; FUI-8766-2022
  • No Thumbnail Available
    Publication
    Vedolizumab treatment in a patient with x-linked agammaglobulinemia, is it safe and efficient?
    (Turkish J Pediatrics, 2019-11-01) Kılıç, Sara Sebnem; KILIÇ GÜLTEKİN, SARA ŞEBNEM; Çekiç, Sükrü; ÇEKİÇ, ŞÜKRÜ; Özgür, Taner; ÖZGÜR, TANER; Özkan, Tanju; ÖZKAN, TANJU MUNEVVER; Karali, Yasin; KARALI, YASİN; Tıp Fakültesi; Pediatri Ana Bilim Dalı; 0000-0002-9574-1842; 0000-0001-5740-9729; 0000-0001-8571-2581; AAG-8416-2021; AAH-1658-2021; L-1933-2017; AAG-8381-2021
    The loss of inflammatory regulation resulting from the absence of B-lymphocytes leads to a risk for autoimmune and autoinflammatory complications. There is no data on the use of Vedolizumab in patients with X-linked agammaglobulinemia (XLA) as well as children with another primary immunodeficiency (PID) diseases. A 4-year-old boy was admitted to our clinic with a history of recurrent respiratory tract infections. He was diagnosed with XLA based on extremely low immunoglobulins, very low level of B cells, genetic mutation of BTK gene, and family history. At the age of 8, he suffered from intermittent fever attacks, abdominal pain, weakness, oral aft, and weight loss. His clinical and laboratory features were consistent with inflammatory bowel disease. Histopathological examination of the biopsy material obtained from terminal ileum, colon and cecum showed Crohn's disease. Initially, he was treated with prednisolone and infliximab. Because of the lack of response, infliximab treatment was switched to adalimumab. Terminal ileum was resected to relieve obstruction complication. Although he had been treated with adalimumab, a significant improvement was not observed. Vedolizumab (Entyvio (TM)), a humanized monoclonal antibody alpha 4 beta 7 integrin-receptor antagonist, was commenced. After treatment with vedolizumab, his fever and abdominal pain attacks reduced, his total daily calorie intake increased and weight gain improved. He began to walk again and continued his school education properly. No side effects were observed in 18 months. This is the first immunocompromised child treated with vedolizumab. The symptoms of the patient receded and no side effect were seen during the treatment.
  • Thumbnail Image
    Publication
    Vedolizumab treatment in a patient with x-linked agammaglobulinemia, is it safe and efficient?
    (Türk Pediatri Dergisi, 2019-11-01) Çekiç, Şükrü; Özgür, Taner; Karalı, Yasin; Özkan, Tanju; Kılıç, Sara Şebnem; ÇEKİÇ, ŞÜKRÜ; ÖZGÜR, TANER; KARALI, YASİN; ÖZKAN, TANJU MUNEVVER; KILIÇ GÜLTEKİN, SARA ŞEBNEM; Tıp Fakültesi; Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı; 0000-0002-9574-1842; 0000-0001-5740-9729; 0000-0001-8571-2581; AAG-8416-2021; AAG-8381-2021; AAH-1658-2021; L-1933-2017; FFS-1974-2022
    The loss of inflammatory regulation resulting from the absence of B-lymphocytes leads to a risk for autoimmune and autoinflammatory complications. There is no data on the use of Vedolizumab in patients with X-linked agammaglobulinemia (XLA) as well as children with another primary immunodeficiency (PID) diseases. A 4-year-old boy was admitted to our clinic with a history of recurrent respiratory tract infections. He was diagnosed with XLA based on extremely low immunoglobulins, very low level of B cells, genetic mutation of BTK gene, and family history. At the age of 8, he suffered from intermittent fever attacks, abdominal pain, weakness, oral aft, and weight loss. His clinical and laboratory features were consistent with inflammatory bowel disease. Histopathological examination of the biopsy material obtained from terminal ileum, colon and cecum showed Crohn's disease. Initially, he was treated with prednisolone and infliximab. Because of the lack of response, infliximab treatment was switched to adalimumab. Terminal ileum was resected to relieve obstruction complication. Although he had been treated with adalimumab, a significant improvement was not observed. Vedolizumab (Entyvio (TM)), a humanized monoclonal antibody alpha 4 beta 7 integrin-receptor antagonist, was commenced. After treatment with vedolizumab, his fever and abdominal pain attacks reduced, his total daily calorie intake increased and weight gain improved. He began to walk again and continued his school education properly. No side effects were observed in 18 months. This is the first immunocompromised child treated with vedolizumab. The symptoms of the patient receded and no side effect were seen during the treatment.
  • No Thumbnail Available
    Publication
    Coexistence of lymphoproliferative syndrome, neurofibromatosis, systemic lupus erythematosus and hyper IgM syndrome in a patient with MSH6 mutation
    (Springer/Plenum Publishers, 2019-02-01) Çekiç, Şükrü; Karalı, Yasin; Kılıç, Sara Şebnem; ÇEKİÇ, ŞÜKRÜ; KARALI, YASİN; KILIÇ GÜLTEKİN, SARA ŞEBNEM; Tıp Fakültesi; İmmunoloji ve Alerji Ana Bilim Dalı; 0000-0002-9574-1842; 0000-0001-8571-2581; AAH-1658-2021; L-1933-2017; ISC-9139-2023
  • No Thumbnail Available
    Publication
    Neurocognitive functions and immunological findings in digeorge syndrome
    (Elsevier, 2023-05-23) Karali, Zuhal; Karali, Yasin; Kılıç, Sara; KARALI, ZUHAL; KARALI, YASİN; KILIÇ GÜLTEKİN, SARA ŞEBNEM; Tıp Fakültesi; Pediatrik İmmünoloji; 0000-0002-6132-2236; CZC-9168-2022; ISC-9139-2023; IDK-5744-2023
  • No Thumbnail Available
    Publication
    Cerebral ischemic attacks in ADA2 deficiency treated with adalimumab
    (Wiley, 2019-08-01) Kılıç, S. S.; Çekiç, S.; Karalı, Y.; KILIÇ GÜLTEKİN, SARA ŞEBNEM; ÇEKİÇ, ŞÜKRÜ; KARALI, YASİN; Tıp Fakültesi; 0000-0001-8571-2581; 0000-0002-9574-1842; L-1933-2017; AAH-1658-2021; ISC-9139-2023
  • No Thumbnail Available
    Publication
    Immunological and neurocognitive functions in digeorge syndrome
    (Wiley, 2023-12-01) Karalı, Z.; Çekiç, S.; Karalı, Y.; Kılıç, S. S.; KARALI, ZUHAL; ÇEKİÇ, ŞÜKRÜ; KARALI, YASİN; KILIÇ GÜLTEKİN, SARA ŞEBNEM; Tıp Fakültesi; 0000-0002-9574-1842; CZC-9168-2022; GBO-8694-2022; IMT-6140-2023; ISC-9139-2023
  • Thumbnail Image
    Publication
    Challenges in investigating patients with isolated decreased serum IgM: The SIMcal study
    (Wiley, 2019-06-01) Janssen, Lisanne M. A.; van Hout, Roeland W. N. M.; de Vries, Esther; Pignata, Claudio; Cirillo, Emilia; Arkwright, Peter D.; Lougaris, Vassilos; Buckland, Matthew; Garcia-Prat, Marina; Soler-Palacin, Pere; Ouederni, Monia; Kralickova, Pavlina; Abolhassani, Hassan; Hammerstroem, Lennart; Aghamohammadi, Asghar; Santos-Perez, Juan L.; Sobh, Ali; ten Bosch, Jutte van de Werff; Henriet, Stefanie; Kılıç, Sara S.; Karalı, Yasin; Ignacio Gonzalez-Granado, Luis; Sediva, Anna; SIMcal Consortium; KILIÇ GÜLTEKİN, SARA ŞEBNEM; KARALI, YASİN; Tıp Fakültesi; Çocuk İmmunoloji Ana Bilim Dalı; AAH-1658-2021; FFS-1974-2022
    The clinical consequences of isolated decreased serum immunoglobulin (Ig)M are not sufficiently known. Therefore, it is difficult to determine the clinical policy following such a finding. Only few reported IgM-deficient patients fulfil the European Society for Immunodeficiencies (ESID) diagnostic criteria for selective IgM deficiency (true sIgMdef), or their diagnosis is uncertain due to insufficient laboratory data (possible sIgMdef). Decreased serum IgM is often incidentally found in asymptomatic adults. The objective of our study was to further characterize true sIgMdef and to compare the European data collected through the ESID Registry community (tertiary centres) to our previously published Dutch cohort (secondary centre). Fifteen centres (12 countries) participated with 98 patients. Patients were excluded if serum IgM was only determined once (n = 14), had normalized (n = 8), or if they also had other immunological abnormalities (n = 15). Ten patients (5 adults) completely fulfilled the ESID criteria for true sIgMdef. Age-matched cut-off values varied widely between centres; when using the ESID diagnostic protocol reference values, only six patients (five adults) had true sIgMdef. Because of these small numbers, further analyses were performed in patients with true or possible sIgMdef (13 adults, 48 children). Respiratory infections were commonly reported at presentation (adults 54%, children 60%). Symptomatic adults had lower serum IgM levels (mean 0.27 g/L, 95% CI 0.22-0.31) than those without symptoms (mean 0.33 g/L, 95% CI 0.30-0.36; P = 0.02). To be able to explore the clinical consequences of true sIgMdef, we should fully analyse and accurately describe those patients in whom a decreased serum IgM is found.
  • No Thumbnail Available
    Publication
    LRBA deficiency in three patients, single center experience
    (Wiley, 2019-08-01) Çekiç, Şükrü; Karali, Yasin; Kılıç, Sara Şebnem; ÇEKİÇ, ŞÜKRÜ; KARALI, YASİN; KILIÇ GÜLTEKİN, SARA ŞEBNEM; Tıp Fakültesi; 0000-0002-9574-1842; 0000-0001-8571-2581; AAH-1658-2021; L-1933-2017